Polyrizon Announces European Patent Office To Publish The Company's Application 'Mucoadhesive Polymers For Nasal Drug Delivery'

The application was published under European publication number EP 4751737. The patent application covers Polyrizon's proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.

Nasal drug delivery has emerged as an increasingly attractive administration route for a wide range of therapeutic compounds, offering rapid onset of action, non-invasive administration, and the potential to bypass gastrointestinal degradation and first-pass metabolism. Polyrizon's technology is intended to address one of the key challenges of nasal administration, limited residence time within the nasal cavity, through the development of advanced mucoadhesive polymer systems.

The publication of the patent application represents a significant milestone in the Company's strategy to strengthen its intellectual property portfolio supporting future pharmaceutical applications and collaborations in the nasal drug delivery field.

"The forthcoming publication of this European patent application marks an important step in strengthening our position in the growing nasal drug delivery market," said Tomer Izraeli, Chief Executive Officer of Polyrizon. "We believe our proprietary mucoadhesive polymer technology has the potential to improve the performance of nasal drug delivery systems across a broad range of therapeutic applications. Expanding our patent portfolio remains a key component of our strategy as we continue to advance innovative solutions for pharmaceutical partners and future product opportunities."

The patent application will continue through the European examination process. If granted, the patent could provide intellectual property protection across multiple European markets, further supporting Polyrizon's potential commercialization and partnering efforts in the pharmaceutical sector.